Helena Foulkes Sells 19,965 Shares of CVS Health Corp (CVS) Stock

CVS Health Corp (NYSE:CVS) EVP Helena Foulkes sold 19,965 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $71.04, for a total value of $1,418,313.60. Following the sale, the executive vice president now directly owns 65,072 shares in the company, valued at approximately $4,622,714.88. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

CVS Health Corp (NYSE CVS) opened at $68.00 on Friday. The stock has a market capitalization of $69,759.22, a P/E ratio of 11.61, a P/E/G ratio of 1.17 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.52 and a current ratio of 1.02. CVS Health Corp has a 12 month low of $66.45 and a 12 month high of $84.00.

CVS Health (NYSE:CVS) last announced its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.88 by $0.04. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The company had revenue of $48.39 billion for the quarter, compared to the consensus estimate of $47.54 billion. During the same period last year, the business posted $1.71 EPS. The company’s revenue was up 5.3% on a year-over-year basis. analysts expect that CVS Health Corp will post 6.37 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, February 2nd. Shareholders of record on Wednesday, January 24th were paid a $0.50 dividend. The ex-dividend date was Tuesday, January 23rd. This represents a $2.00 annualized dividend and a dividend yield of 2.94%. CVS Health’s dividend payout ratio (DPR) is currently 30.91%.

Several hedge funds have recently made changes to their positions in CVS. Jackson Grant Investment Advisers Inc. boosted its stake in shares of CVS Health by 0.6% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 2,881 shares of the pharmacy operator’s stock valued at $232,000 after buying an additional 18 shares in the last quarter. Sequoia Financial Advisors LLC boosted its stake in shares of CVS Health by 0.8% in the second quarter. Sequoia Financial Advisors LLC now owns 6,406 shares of the pharmacy operator’s stock valued at $515,000 after buying an additional 53 shares in the last quarter. Brookstone Capital Management boosted its stake in shares of CVS Health by 1.8% in the second quarter. Brookstone Capital Management now owns 3,153 shares of the pharmacy operator’s stock valued at $254,000 after buying an additional 55 shares in the last quarter. Summit Asset Management LLC boosted its stake in shares of CVS Health by 2.0% in the second quarter. Summit Asset Management LLC now owns 5,172 shares of the pharmacy operator’s stock valued at $416,000 after buying an additional 100 shares in the last quarter. Finally, Meiji Yasuda Life Insurance Co boosted its stake in shares of CVS Health by 0.3% in the second quarter. Meiji Yasuda Life Insurance Co now owns 38,147 shares of the pharmacy operator’s stock valued at $3,069,000 after buying an additional 100 shares in the last quarter. Institutional investors own 83.23% of the company’s stock.

Several brokerages have recently weighed in on CVS. Loop Capital cut their target price on CVS Health from $83.00 to $73.00 and set a “hold” rating on the stock in a research report on Tuesday, November 7th. Morgan Stanley raised CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 target price on the stock in a research report on Friday, January 5th. Needham & Company LLC raised their target price on CVS Health from $85.00 to $88.00 and gave the stock a “buy” rating in a research report on Tuesday, January 2nd. SunTrust Banks raised their target price on CVS Health to $90.00 and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, Leerink Swann set a $85.00 target price on CVS Health and gave the stock a “buy” rating in a research report on Friday, February 9th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $87.82.

ILLEGAL ACTIVITY NOTICE: “Helena Foulkes Sells 19,965 Shares of CVS Health Corp (CVS) Stock” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/23/helena-foulkes-sells-19965-shares-of-cvs-health-corp-cvs-stock.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Insider Buying and Selling by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply